Additionally, recent phase I clinical studies found that ALT-803, an IL-15 superagonist, increased the number of circulating NK cells resulting in enhanced pro-inflammation and tumor growth arrest in patients with advanced sold tumors (Fantini et al., 2019). Here, IL15 is linked to neoplasm.